



Wen-Kai Weng, MD, PhD

Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy) and, by courtesy, of Dermatology

Medicine - Blood & Marrow Transplantation

CLINICAL OFFICE (PRIMARY)

- **Stanford Cancer Center**

875 Blake Wilbur Dr Clinic F

MC 6560

Stanford, CA 94305

Tel (650) 498-6000 **Fax** (650) 498-6919

ACADEMIC CONTACT INFORMATION

- **Alternate Contact**

Jenny McGuire - Administrative Assistant

Email jennymcg@stanford.edu

Tel 650-723-0837

Bio

BIO

Dr. Wen-Kai Weng specializes in the treatment of non-Hodgkin's lymphoma (NHL), his basic research interest is immunotherapy for lymphoma and cancer, with two components: tumor specific targeting therapy and allogeneic transplant. He is currently working on new strategies to target patient-specific tumor using antibody along with effector cells. He is also conducting clinical study looking at the clinical efficacy of allogeneic transplant in patients with cutaneous lymphoma.

CLINICAL FOCUS

- Cancer > Blood and Marrow Transplant
- Cancer > Lymphoma
- Cutaneous T-Cell Lymphoma
- Medical Oncology
- Chimeric Antigen Receptor (CAR) T-cell Therapy
- Immunotherapy

ACADEMIC APPOINTMENTS

- Associate Professor - University Medical Line, Medicine - Blood & Marrow Transplantation
- Associate Professor - University Medical Line (By courtesy), Dermatology
- Member, Stanford Cancer Institute

ADMINISTRATIVE APPOINTMENTS

- Scientific Advisory Board, Lymphoma Research Foundation, (2011-2012)
- Co-Director, Stanford Multidisciplinary Cutaneous Lymphoma Clinic, (2014- present)
- Director, Blood and Marrow Transplantation/Cellular Therapy (BMT/CT) Fellowship Program, (2015- present)

HONORS AND AWARDS

- Predoctoral National Research Service Award, NIH/NIAID (1994-1995)
- Doctoral Dissertation Award, University of Minnesota Graduate School (1995)
- Charles and Dorothy Andrew Bird Award, Sigma Xi Scientific Research Society (1996)
- Fellowship, Lymphoma Research Foundation (2002-2004)
- K08 Clinical Scientist Career Development Award, NIH/NCI (2005-2009)
- Developmental Research Award, Stanford University Cancer Center (2009-2010)
- ITI Seed Grant Award, Institute for Immunity, Transplantation and Infection, Stanford University (2011-2012)
- Developmental Research Award, Stanford Cancer Institute (2012-2013)
- Translational Research Grant, Stanford Cancer Institute (2014-2015)
- Division Teaching Award, BMT, Stanford University (2009, 2010, 2012, 2015, 2016, 2018, 2019)
- Department of Medicine Master Teacher Award, Stanford University (2022)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Co-Director, Stanford Cancer Immunotherapy and Blood & Marrow Transplantation Symposium (2018 - 2025)

PROFESSIONAL EDUCATION

- Board Certification: Medical Oncology, American Board of Internal Medicine (2021)
- Fellowship, Stanford University , Medical Oncology (2002)
- Residency, University of Texas-Houston , Internal Medicine (1999)
- Internship, University of Texas-Houston , Internal Medicine (1997)
- PhD, University of Minnesota , Pathobiology/Immunology (1996)
- MD, ChungShan Medical and Dental College , Medicine (1988)

PATENTS

- Ronald Levy, Wen-Kai Weng. "United States Patent 9109255 Methods and compositions for determining responsiveness to antibody therapy", Aug 18, 2015

LINKS

- Wen-Kai Weng, MD, PhD: <https://web.stanford.edu/~wkweng/weng.home.htm>
- Get a Second Opinion: <https://stanfordhealthcare.org/second-opinion/overview.html>
- Bird Calendar Fund Raising: <https://web.stanford.edu/~wkweng/calendar/CalendarFrontPage.htm>

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

My clinical focus is non-Hodgkin's lymphoma (NHL) and am currently conducting clinical trials with novel therapies on these patients. My basic research interest is immunotherapy for lymphoma, with two components: tumor vaccines and allogeneic transplant. For the tumor vaccine, I am working with my colleagues in Oncology to conduct a clinical trial using a CpG-activated tumor vaccine in mantle cell NHL patients who undergo autologous transplantation. The goal is to sensitize the autologous T cells to recognize the malignant lymphoma cells and to expand these tumor-specific T cells immediate after autologous transplant.

Second, I am conducting a study using a novel non-myeloablative preparative regimen prior to allogeneic transplant in patients with mycosis fungoides/Sezary syndrome, a cutaneous T cell NHL. While these patients exhibit little sensitivity to traditional chemotherapy, graft-versus-lymphoma effect provided by allogeneic transplant seems to have an excellent disease control effect. I also use high throughput sequencing technology to assess the minimal residual disease and the immune reconstitution after allogeneic transplant.

CLINICAL TRIALS

- A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors, Recruiting
- A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression, Recruiting
- Expanded Access Protocol (EAP) for Nonconforming (NC) Afami-cel, Recruiting
- Long-term Follow-up Study of Subjects w/ Malignancies Treated With CRISPR CAR Cellular Therapies, Recruiting
- Phase I GD2 CAR T Cells for H3K27M-mutant Diffuse Midline Glioma (DMG), Recruiting
- Protocol for Research DB for HCT, Other Cellular Therapies and Marrow Toxic Injuries, Recruiting
- Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing, Recruiting
- Allogeneic HCT vs Hypomethylating Tx or Best Supportive Care in High Risk MDS, Not Recruiting
- Allogeneic Transplantation Using TLI & ATG for Older Patients with Hematologic Malignancies, Not Recruiting
- Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma, Not Recruiting
- Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment, Not Recruiting
- Expanded Access KTE-X19 in Relapsed/Refractory B-Cell Malignancies, Not Recruiting
- Extension LTFU & Lenalidomide Maintenance Tx for Enrollees on BMT CTN 0702 , Not Recruiting
- Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD), Not Recruiting
- Non-myeloablative Allogeneic Transplantation +/- Allogeneic Idiotype Pulsed Dendritic Cells for MM, Not Recruiting
- Phase 1/2 Safety and Efficacy of CTX131 in Adults with Hematologic Malignancies, Not Recruiting
- Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT, Not Recruiting
- Phase I Primary T Regulatory Cell Tx to Treat Visceral Acute GVHD After HCT, Not Recruiting
- Phase I/II Anti-CD7 CAR-TCells in R/R T-Cell AcuteLymphoblasticLeukemia/T-Cell LymphoblasticLymphoma, Not Recruiting
- Phase I/II Anti-CD70CRISPR-Cas9-Engineered TCells(CTX130) in Relapsed/Refractory T/BCellMalignancies, Not Recruiting
- Phase I/II KTE-C19 in Combo w/ Atezolizumab in Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Not Recruiting
- Phase II Allogeneic CD8 Memory T-Cells Infusion as Consolidative Tx After HCT in Leukemia & Lymphoma, Not Recruiting
- Phase II Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG in MM, Not Recruiting
- Phase II Donor Statin Tx for Prevention of Severe Acute GVHD after Myeloablative HCT, Not Recruiting
- Phase II KTE-X19 in Relapsed/Refractory Mantle Cell Lymphoma, Not Recruiting
- Phase II Non-myeloablative Allogeneic Transplant Using TLI & ATG In Cutaneous T Cell Lymphoma, Not Recruiting
- Phase II Novel Approaches for GVHD Prevention Compared to Contemporary Controls, Not Recruiting
- Phase II Obinutuzumab in Prevention of cGVHD After Allogeneic Peripheral Blood Stem Cell Transplant, Not Recruiting
- Phase II Optimizing Post-Allogeneic HCT Outcomes in Lymphoma Using Ibrutinib, Not Recruiting
- Phase II Ruxolitinib in Combo w/ Corticosteroids in Steroid-Refractory Acute Graft-vs-Host Disease, Not Recruiting
- Phase II Tabelecleucel in Epstein-BarrVirus-Associated Viremia /Malignancy Who Have No AlternativeTx, Not Recruiting
- Phase II: HD Chemo + Allo Hematopoietic Cell Transplant for NHL, Not Recruiting
- Phase III Axicabtagene Ciloleucel vs SoC Therapy in Relapsed/Refractory Diffuse Large BCell Lymphoma, Not Recruiting

- Phase III FLT3Inhibitor Gilteritinib Maintenance Therapy After Allogeneic Transplant in FLT3/ITD AML, Not Recruiting
- Phase III Standard-Dose Combo Chemo or High-Dose Combo Chemo +Stem Cell T-plant in Germ Cell Tumors, Not Recruiting
- Phase III Umbilical Cord Blood vs Bone Marrow in Hematologic Malignancies, Not Recruiting
- Single Autologous Tplant +/- Consolidation Therapy VS Tandem Autologous Tplant +Lenalidomide for MM, Not Recruiting
- Tandem Autologous Transplant vs. Non-Myeloablative Allogeneic Transplant for Multiple Myeloma, Not Recruiting
- TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD, Not Recruiting
- Transplantation for Patients with CLL, Not Recruiting
- Bone Marrow Grafting for Leukemia and Lymphoma, Not Specified

Teaching

GRADUATE AND FELLOWSHIP PROGRAM AFFILIATIONS

- Cancer Biology (Phd Program)
- Medicine (Masters Program)

Publications

PUBLICATIONS

- **Dynamics of BCMA expression in patients with relapsed/refractory multiple myeloma receiving BCMA-directed CAR-T therapy.** *Blood cancer journal*
Rana, M. S., Fernandez-Pol, S., Jensen, A., Hovanky, V., Velayati, A., Oak, J. S., Silva, O., Ames, E., Muffly, L. S., Sahaf, B., Arai, S., Kennedy, V. E., Bharadwaj, et al
2026
- **Superior Chronic GVHD-Free Survival with Post-Transplant Cyclophosphamide Relative to Tacrolimus/Methotrexate in Myeloablative HLA-Matched Allogeneic Hematopoietic Cell Transplantation.** *Transplantation and cellular therapy*
Molina, A., Bubb, Q. R., Srinagesh, H. K., Yee, R., Arai, S., Bharadwaj, S., Dahiya, S., Elmariah, H., Frank, M., Hosoya, H., Johnston, L., Meyer, E., Mikkilineni, et al
2026
- **Early Steroid and Anakinra Use to Manage Axicabtagene Ciloleucel Toxicity Reduces the Total Duration of CRS and ICANS.** *Blood advances*
Wang, W. L., Lee, D., Cheung, E., Jensen, A., Rana, M. S., Goyal, A., Hamilton, M. P., Ghalehsari, N., Latchford, T., Scott, B. J., Mallampet, J., Heng, E., Khan, et al
2026
- **Stem cell therapy for ischemic stroke: neuroimaging approaches and evidence from a systematic review.** *Frontiers in neurology*
Jiang, B., Zhao, M., Tong, E., Liu, Y., Fettahoglu, A., Weng, W. K., Moseley, M. E., Wintermark, M., Steinberg, G. K., Zaharchuk, G.
2026; 17: 1718086
- **Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 Cohort 3.** *Blood*
van Meerten, T., Kersten, M. J., Iacoboni, G., Hess, G. R., Mutsaers, P. G., Martin Garcia-Sancho, A. M., Goy, A., Gine, E., Hill, B. T., Weng, W. K., Reagan, P. M., Patel, K., Galal, et al
2025
- **The Impact of Anti-CD38 Monoclonal Antibody Therapy on Stem-Cell Mobilization Yields in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Referred from Community and Academic Oncology Practices: Single Center, Real World Data 2021-2024.** *Transplantation and cellular therapy*
Uzun, D., Paul, J. M., Jensen, A., Tamaresis, J., Domingo, W., Arai, S., Ventura, F. A., Rocha, J., Bennett, L., Jones, A., Bharadwaj, S., Johnston, L., Lowsky, et al
2025
- **Fatal Recurrence of IEC-HS Following Autologous Stem Cell Boost in Patients Receiving BCMA CAR-T Cell Therapy.** *Blood advances*
Ananth, S., Torres, N. E., Sahaf, B., Mikkilineni, L., Fernandez-Pol, S., Salmi, D., Negrin, R. S., Shiraz, P., Smith, M., Bharadwaj, S., Weng, W. K., Kennedy, V. E., Dahiya, et al

2025

- **ASTCT and USCLC Clinical Practice Recommendations for Allogeneic Stem Cell Transplant in Mycosis Fungoides and Sézary Syndrome.** *Journal of the American Academy of Dermatology*
Goyal, A., O'Leary, D., Dabaja, B., Weng, W. K., Zain, J., Cutler, C., Guitart, J., Kim, Y. H., Geskin, L. J., Hoppe, R. T., Wilson, L. D., Beaven, A. W., Horwitz, et al
2025
- **Efficacy of Hedgehog Pathway Inhibitors as Adjuvant in Treating Steroid-Refractory Sclerodermatous Chronic Graft-Versus-Host Disease.** *Journal of the American Academy of Dermatology*
Mendez-Hernandez, A., Gupta, R., Arai, S., Lowsky, R., Kwong, B., Weng, W. K.
2025
- **Donor Regulatory T-Cell Therapy to Prevent Graft-Versus-Host Disease.** *Blood*
Meyer, E., Pavlova, A., Villar-Prados, A., Bader, C. S., Xie, B., Muffly, L., Kim, P., Sutherland, K. C., Bharadwaj, S., Dahiya, S., Frank, M. J., Arai, S., Johnston, et al
2025
- **Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study.** *The Lancet. Oncology*
Iyer, S. P., Sica, R. A., Ho, P. J., Prica, A., Zain, J., Foss, F. M., Hu, B., Beitinjaneh, A., Weng, W. K., Kim, Y. H., Khodadoust, M. S., Huen, A. O., Williams, et al
2024
- **A 17-Year Experience of a Large Dedicated Fellowship in Blood and Marrow Transplantation and Cellular Therapy: A Blueprint for Modern Day Training Program.** *Journal of cancer education : the official journal of the American Association for Cancer Education*
Bharadwaj, S., Lowsky, R., Mikkilineni, L., Smith, M., Weng, W. K.
2024
- **Belumosudil combination therapy for chronic graft-versus-host-disease in real-world clinical practice.** *Bone marrow transplantation*
Chin, M. M., Tamaresis, J. S., Johnston, L. J., Lowsky, R., Meyer, E., Muffly, L., Shiraz, P., Frank, M. J., Rezvani, A. R., Bharadwaj, S., Weng, W. K., Shizuru, J. A., Arai, et al
2024
- **CD22-Directed CAR T-Cell Therapy Achieves Complete Remission in CD19-Directed CAR T-Cell Refractory Follicular and Mantle Cell Lymphoma**
Kramer, A., Srinagesh, H., Su, Y., Hamilton, M. P., Levine, K., Migliore, E., Denoble, K., Brown, A. K., Cunanan, K., Agarwal, N., Lohman, C., Mavroukakis, S., Bharadwaj, et al
ELSEVIER.2024: 2064-2066
- **Phase II study of novel CXCR2 agonist and Plerixafor for rapid stem cell mobilization in patients with multiple myeloma.** *Blood cancer journal*
Sidana, S., Bankova, A. K., Hosoya, H., Kumar, S. K., Holmes, T. H., Tamaresis, J., Le, A., Muffly, L. S., Maysel-Auslender, S., Johnston, L., Arai, S., Lowsky, R., Meyer, et al
2024; 14 (1): 173
- **ASTCT and USCLC Clinical Practice Recommendations for Allogeneic Stem Cell Transplant in Mycosis Fungoides and Sézary Syndrome.** *Transplantation and cellular therapy*
Goyal, A., O'Leary, D., Dabaja, B., Weng, W. K., Zain, J., Cutler, C., Guitart, J., Kim, Y. H., Geskin, L. J., Hoppe, R. T., Wilson, L. D., Beaven, A. W., Horwitz, et al
2024
- **CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study.** *Lancet (London, England)*
Frank, M. J., Baird, J. H., Kramer, A. M., Srinagesh, H. K., Patel, S., Brown, A. K., Oak, J. S., Younes, S. F., Natkunam, Y., Hamilton, M. P., Su, Y. J., Agarwal, N., Chinnasamy, et al
2024
- **A Phase 1 Clinical Trial of NKTR-255 with CD19-22 CAR-T Cell Therapy for Refractory B-cell Acute Lymphoblastic Leukemia.** *Blood*
Srinagesh, H. K., Jackson, C., Shiraz, P., Jeyakumar, N., Hamilton, M. P., Egeler, E., Mavroukakis, S., Kuo, A., Cancilla, J., Sahaf, B., Agarwal, N., Kanegai, A. M., Kramer, et al
2024

- **Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma.** *Journal for immunotherapy of cancer*
Bharadwaj, S., Lau, E., Hamilton, M. P., Goyal, A., Srinagesh, H., Jensen, A., Lee, D., Mallampet, J., Elkordy, S., Syal, S., Patil, S., Latchford, T., Sahaf, et al
2024; 12 (7)
- **Long-term remission with allogeneic transplant in patients with refractory/relapsed cutaneous cytotoxic T-cell lymphoma.** *Blood neoplasia*
Weng, W. K., Iragavarapu, C., Weng, G. M., Hoppe, R. T., Hiniker, S., Khodadoust, M. S., Kim, Y. H.
2024; 1 (2): 100007
- **Management of post-autologous transplant relapse in patients with T-cell lymphomas.** *American journal of hematology*
Veilleux, O., Socola, F., Arai, S., Frank, M. J., Johnston, L., Lowsky, R., Shizuru, J., Meyer, E., Muffly, L., Rezvani, A. R., Shiraz, P., Sidana, S., Dahiya, et al
2024
- **Tablecleucel for EBV+ PTLD following allogeneic HCT or SOT in a multicenter expanded access protocol.** *Blood advances*
Nikiforow, S., Whangbo, J. S., Reshef, R., Tsai, D. E., Bunin, N. J., Abu-Arja, R. F., Mahadeo, K. M., Weng, W. K., Van Besien, K., Loeb, D., Nasta, S. D., Nemecek, E. R., Zhao, et al
2024
- **CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity.** *Blood advances*
Hamilton, M. P., Craig, E., Gentile Sanchez, C., Mina, A., Tamaresis, J., Kirmani, N., Ehlinger, Z., Syal, S., Good, Z., Sworder, B., Schroers-Martin, J., Lu, Y., Muffly, et al
2024
- **A US Multicenter Collaborative Study on Outcomes of Hematopoietic Cell Transplantation in Hepatosplenic T-Cell Lymphoma.** *Transplantation and cellular therapy*
Moustafa, M. A., Ramdial, J. L., Tsalatsanis, A., Khimani, F., Dholaria, B., Bojanini, L., Brooks, T., Zain, J., Bennani, N. N., Braunstein, Z., Brammer, J. E., Beitinjaneh, A., Jagadeesh, et al
2024
- **Clinical characteristics, treatment patterns, and outcomes of cytotoxic cutaneous T-cell lymphomas.** *American journal of hematology*
Mou, E., Fernandez-Pol, S., Li, S., Rieger, K. E., Novoa, R., Suarez, C. J., Wieland, R., Weng, W., Kim, Y. H., Khodadoust, M. S.
2024
- **Clinical Features of Neurotoxicity Following CD19 CAR T-cell Therapy in Mantle Cell Lymphoma.** *Blood advances*
Nie, E. H., Su, Y. J., Baird, J. H., Agarwal, N., Bharadwaj, S., Weng, W. K., Smith, M., Dahiya, S., Han, M. H., Dunn, J. E., Kipp, L. B., Miklos, D. B., Scott, et al
2024
- **Single Center Randomized Trial of T-reg graft alone versus T-reg graft Plus Tacrolimus for the Prevention of Acute GVHD.** *Blood advances*
Bader, C. S., Pavlova, A., Lowsky, R., Muffly, L., Shiraz, P., Arai, S., Johnston, L. J., Rezvani, A. R., Weng, W. K., Miklos, D. B., Frank, M. J., Tamaresis, J. S., Agrawal, et al
2023
- **Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents.** *Blood*
Spinner, M. A., Sica, R. A., Tamaresis, J. S., Lu, Y., Chang, C., Lowsky, R., Frank, M. J., Johnston, L. J., Miklos, D. B., Muffly, L., Negrin, R. S., Rezvani, A. R., Shiraz, et al
2023
- **Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia in the Modern Era.** *Transplantation and cellular therapy*
Liang, E. C., Craig, J., Torelli, S., Cunanan, K., Iglesias, M., Arai, S., Frank, M. J., Johnston, L., Lowsky, R., Meyer, E. H., Miklos, D. B., Negrin, R., Rezvani, et al
2022
- **Real-world Experience of Cryopreserved Allogeneic Hematopoietic Grafts in the COVID-19 Pandemic: A Single Center Report.** *Transplantation and cellular therapy*
Bankova, A. K., Caveney, J., Yao, B., Ramos, T. L., Bogeholz, J., Heydari, K., Diaz, N., Jackson, M. L., Lowsky, R., Brown, J. W., Johnston, L., Rezvani, A. R., Frank, et al
1800

- **Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy** *BLOOD ADVANCES*
Johnsrud, A., Craig, J., Baird, J., Spiegel, J., Muffly, L., Zehnder, J., Tamaresis, J., Negrin, R., Johnston, L., Arai, S., Shizuru, J., Lowsky, R., Meyer, et al
2021; 5 (21): 4465-4475
- **Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia.** *Blood advances*
Muffly, L., Sundaram, V., Chen, C., Yurkiewicz, I., Kuo, E., Burnash, S., Spiegel, J. Y., Arai, S., Frank, M. J., Johnston, L. J., Lowsky, R., Meyer, E. H., Negrin, et al
2021; 5 (16): 3147-3151
- **NUTRITIONAL DEFICIENCY CONTRIBUTING TO REFRACTORY ERYTHRODERMA IN HEMATOPOETIC CELL TRANSPLANT PATIENTS: DISTINCTIVE CLINICAL AND HISTOPATHOLOGICAL FINDINGS.** *Journal of the American Academy of Dermatology*
Winge, M. C., Rieger, K. E., Kim, J., Weng, W., Johnston, L. J., Miklos, D. B., Strelow, J., Zaba, L. C., Pugliese, S. B., Novoa, R. A., Kwong, B. Y.
2021
- **CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial.** *Nature medicine*
Spiegel, J. Y., Patel, S., Muffly, L., Hossain, N. M., Oak, J., Baird, J. H., Frank, M. J., Shiraz, P., Sahaf, B., Craig, J., Iglesias, M., Younes, S., Natkunam, et al
2021
- **Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma.** *Bone marrow transplantation*
Lemieux, C., Muffly, L. S., Iberri, D. J., Craig, J. K., Johnston, L. J., Lowsky, R., Shiraz, P., Rezvani, A. R., Frank, M. J., Weng, W., Meyer, E., Shizuru, J. A., Arai, et al
2021
- **Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor vs. G-CSF +/- Plerixafor in the Lenalidomide Era.** *Transplantation and cellular therapy*
Johnsrud, A., Ladha, A., Muffly, L., Shiraz, P., Goldstein, G., Osgood, V., Shizuru, J. A., Johnston, L., Arai, S., Weng, W., Lowsky, R., Rezvani, A. R., Meyer, et al
2021
- **Radiation Therapy for Primary Cutaneous Gamma Delta Lymphoma Prior to Stem Cell Transplantation.** *Cancer investigation*
Wu, Y. F., Skinner, L., Lewis, J., Khodadoust, M. S., Kim, Y. H., Kwong, B. Y., Weng, W., Hoppe, R. T., Sodji, Q., Hui, C., Kastelowitz, N., Fernandez-Pol, S., Hiniker, et al
2021: 1–11
- **Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.** *Transplantation and cellular therapy*
Liang, E. C., Muffly, L. S., Shiraz, P., Shizuru, J. A., Johnston, L., Arai, S., Frank, M. J., Weng, W., Lowsky, R., Rezvani, A., Meyer, E. H., Negrin, R., Miklos, et al
2021
- **Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma** *BLOOD ADVANCES*
Baird, J. H., Epstein, D. J., Tamaresis, J. S., Ehlinger, Z., Spiegel, J. Y., Craig, J., Claire, G. K., Frank, M. J., Muffly, L., Shiraz, P., Meyer, E., Arai, S., Brown, et al
2021; 5 (1): 143–55
- **Pembrolizumab in mycosis fungoides with PD-L1 structural variants.** *Blood advances*
Beygi, S. n., Fernandez-Pol, S. n., Duran, G. n., Wang, E. B., Stehr, H. n., Zehnder, J. L., Ramchurren, N. n., Fling, S. P., Cheever, M. A., Weng, W. K., Kim, Y. H., Khodadoust, M. S.
2021; 5 (3): 771–74
- **Incidence and Risk Factors Associated with Bleeding and Thrombosis Following Chimeric Antigen Receptor T Cell Therapy.** *Blood advances*
Johnsrud, A. J., Craig, J., Baird, J. H., Spiegel, J. Y., Muffly, L., Zehnder, J. L., Tamaresis, J. S., Negrin, R. S., Johnston, L., Arai, S., Shizuru, J. A., Lowsky, R., Meyer, et al
2021

- **Outcomes with Autologous or Allogeneic Stem Cell Transplantation in Patients with Plasma Cell Leukemia in the Era of Novel Agents.** *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*
Lemieux, C., Johnston, L. J., Lowsky, R., Muffly, L. S., Craig, J. K., Shiraz, P., Rezvani, A., Frank, M. J., Weng, W., Meyer, E., Shizuru, J., Arai, S., Negrin, et al
2020
- **Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial.** *The Journal of experimental medicine*
Frank, M. J., Khodadoust, M. S., Czerwinski, D. K., Haabeth, O. A., Chu, M. P., Miklos, D. B., Advani, R. H., Alizadeh, A. A., Gupta, N. K., Maeda, L. S., Reddy, S. A., Laport, G. G., Meyer, et al
2020; 217 (9)
- **CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR-Refractory Large B-Cell Lymphoma.** *Blood*
Baird, J. H., Frank, M. J., Craig, J. n., Patel, S. n., Spiegel, J. Y., Sahaf, B. n., Oak, J. S., Younes, S. n., Ozawa, M. n., Yang, E. n., Natkunam, Y. n., Tamaresis, J. S., Ehlinger, et al
2020
- **Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma.** *Blood advances*
Weng, W. K., Arai, S. n., Rezvani, A. n., Johnston, L. n., Lowsky, R. n., Miklos, D. n., Shizuru, J. n., Muffly, L. n., Meyer, E. n., Negrin, R. S., Wang, E. n., Almazan, T. n., Million, et al
2020; 4 (18): 4474–82
- **Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma.** *Bone marrow transplantation*
Lemieux, C. n., Muffly, L. S., Rezvani, A. n., Lowsky, R. n., Iberri, D. J., Craig, J. K., Frank, M. J., Johnston, L. J., Liedtke, M. n., Negrin, R. n., Weng, W. K., Meyer, E. n., Shizuru, et al
2020
- **Pityriasis rubra pilaris-like graft-vs-host disease following allogeneic stem cell transplant in two patients.** *Clinical case reports*
Wang, J. Y., Tabata, M. M., Pugliese, S., Phillips, D., Kim, J., Weng, W. K., Kwong, B. Y.
2019; 7 (12): 2491-2494
- **Volumetric Modulated Arc Therapy and 3-Dimensional Printed Bolus in the Treatment of Refractory Primary Cutaneous Gamma Delta Lymphoma of the Bilateral Legs** *PRACTICAL RADIATION ONCOLOGY*
Obeid, J., Gutkin, P. M., Lewis, J., Skinner, L., Wang, E. B., Khodadoust, M. S., Kim, Y. H., Weng, W., Hoppe, R. T., Hiniker, S. M.
2019; 9 (4): 220–25
- **Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients** *JCI INSIGHT*
Meyer, E. H., Laport, G., Xie, B. J., MacDonald, K., Heydari, K., Sahaf, B., Tang, S., Baker, J., Armstrong, R., Tate, K., Tadisco, C., Arai, S., Johnston, et al
2019; 4 (10)
- **Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort.** *Blood advances*
Spinner, M. A., Kennedy, V. E., Tamaresis, J. S., Lavori, P. W., Arai, S. n., Johnston, L. J., Meyer, E. H., Miklos, D. B., Muffly, L. S., Negrin, R. S., Rezvani, A. R., Shizuru, J. A., Weng, et al
2019; 3 (16): 2454–64
- **Infusion of donor-derived CD8(+) memory T cells for relapse following allogeneic hematopoietic cell transplantation** *BLOOD ADVANCES*
Muffly, L., Sheehan, K., Armstrong, R., Jensen, K., Tate, K., Rezvani, A. R., Miklos, D., Arai, S., Shizuru, J., Johnston, L., Meyer, E., Weng, W., Laport, et al
2018; 2 (6): 681–90
- **Potential Association of Anti-CCR4 Antibody Mogamulizumab and Graft-vs-Host Disease in Patients With Mycosis Fungoides and Sézary Syndrome.** *JAMA dermatology*
Dai, J. n., Almazan, T. H., Hong, E. K., Khodadoust, M. S., Arai, S. n., Weng, W. K., Kim, Y. H.
2018
- **Effect of voriconazole on risk of nonmelanoma skin cancer after hematopoietic cell transplantation** *JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY*
Kuklinski, L. F., Li, S., Karagas, M. R., Weng, W., Kwong, B. Y.
2017; 77 (4): 706–12

- **Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Veeraputhiran, M., Yang, L., Sundaram, V., Arai, S., Lowsky, R., Miklos, D., Meyer, E., Muffy, L., Negrin, R., Rezvani, A., Shizuru, J., Weng, W., Johnston, et al
2017; 23 (10): 1744–48
- **Gain of CD26 expression on the malignant T-cells in relapsed erythrodermic leukemic mycosis fungoides.** *Journal of cutaneous pathology*
Cedeno-Laurent, F., Wysocka, M., Obstfeld, A. E., Novoa, R. A., Vittorio, C. C., Kim, E. J., Weng, W., Rook, A. H.
2017
- **HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity.** *Blood advances*
Spinner, M. A., Fernández-Viña, M. n., Creary, L. E., Quinn, O. n., Elder, L. n., Arai, S. n., Johnston, L. J., Meyer, E. H., Miklos, D. B., Muffy, L. S., Negrin, R. S., Shizuru, J. A., Weng, et al
2017; 1 (17): 1347–57
- **Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.** *Journal of clinical oncology*
Kim, Y. H., Tavallaee, M., Sundram, U., Salva, K. A., Wood, G. S., Li, S., Rozati, S., Nagpal, S., Krathen, M., Reddy, S., Hoppe, R. T., Nguyen-Lin, A., Weng, et al
2015; 33 (32): 3750-3758
- **Genomic analysis of mycosis fungoides and Sézary syndrome identifies recurrent alterations in TNFR2.** *Nature genetics*
Ungewickell, A., Bhaduri, A., Rios, E., Reuter, J., Lee, C. S., Mah, A., Zehnder, A., Ohgami, R., Kulkarni, S., Armstrong, R., Weng, W., Gratzinger, D., Tavallaee, et al
2015; 47 (9): 1056-1060
- **Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms.** *Biology of blood and marrow transplantation*
Benjamin, J., Chhabra, S., Kohrt, H. E., Lavori, P., Laport, G. G., Arai, S., Johnston, L., Miklos, D. B., Shizuru, J. A., Weng, W., Negrin, R. S., Lowsky, R.
2014; 20 (6): 837-843
- **European LeukemiaNet classification intermediate risk-1 cohort is associated with poor outcomes in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation** *BLOOD CANCER JOURNAL*
Medeiros, B. C., Tian, L., Robenson, S., Laport, G. G., JOHNSTON, L. J., Shizuru, J. A., Miklos, D. B., Arai, S., Benjamin, J. E., Weng, W., Negrin, R. S., Lowsky, R.
2014; 4
- **Cancer Vaccines and T Cell Therapy** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Rezvani, K., Brody, J. D., Kohrt, H. E., Logan, A. C., Advani, R., Czerwinski, D. K., Weng, W., Negrin, R. S., Carlton, V., Faham, M., Levy, R., Barrett, J.
2013; 19 (1): S97-S101
- **Minimal residual disease monitoring with high-throughput sequencing of T cell receptors in cutaneous T cell lymphoma** *SCIENCE TRANSLATIONAL MEDICINE*
Weng, W. K., Armstrong, R., Arai, S., Desmarais, C., Hoppe, R., Kim, Y. H.
2013; 5 (214): 214ra171
- **Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence** *BLOOD*
Arai, S., Sahaf, B., Narasimhan, B., Chen, G. L., Jones, C. D., Lowsky, R., Shizuru, J. A., Johnston, L. J., Laport, G. G., Weng, W., Benjamin, J. E., Schaeffer, J., Brown, et al
2012; 119 (25): 6145-6154
- **The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients** *AMERICAN JOURNAL OF HEMATOLOGY*
Kelly-Sell, M. J., Kim, Y. H., Straus, S., Benoit, B., Harrison, C., Sutherland, K., Armstrong, R., Weng, W., Showe, L. C., Wysocka, M., Rook, A. H.
2012; 87 (4): 354-360
- **Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma** *BONE MARROW TRANSPLANTATION*

- Chen, A. I., Negrin, R. S., McMillan, A., Shizuru, J. A., JOHNSTON, L. J., Lowsky, R., Miklos, D. B., Arai, S., Weng, W., Laport, G. G., Stockerl-Goldstein, K.
2012; 47 (4): 516-521
- **Transcriptome sequencing in Sezary syndrome identifies Sezary cell and mycosis fungoides-associated lncRNAs and novel transcripts** *BLOOD*
Lee, C. S., Ungewickell, A., Bhaduri, A., Qu, K., Webster, D. E., Armstrong, R., Weng, W. K., Aros, C. J., Mah, A., Chen, R. O., Lin, M., Sundram, U., Chang, et al
2012; 120: 3288-3297
 - **Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Laport, G. G., Sheehan, K., Baker, J., Armstrong, R., Wong, R. M., Lowsky, R., Johnston, L. J., Shizuru, J. A., Miklos, D., Arai, S., Benjamin, J. E., Weng, W., Negrin, et al
2011; 17 (11): 1679-1687
 - **Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Arai, S., Letsinger, R., Wong, R. M., Johnston, L. J., Laport, G. G., Lowsky, R., Miklos, D. B., Shizuru, J. A., Weng, W., Lavori, P. W., Blume, K. G., Negrin, R. S., Horning, et al
2010; 16 (8): 1145-1154
 - **The IgG Fc Receptor FcγRIIIa 158 V/F Polymorphism is Correlated with Rituximab-Induced Neutropenia after Autologous Transplantation in Patients with Non-Hodgkin Lymphoma** *JOURNAL OF CLINICAL ONCOLOGY*
Weng, W. K., Negrin, R., Lavori, P., Horning, S. J.
2010; 28: 279-284
 - **TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors** *BLOOD*
Kohrt, H. E., Turnbull, B. B., Heydari, K., Shizuru, J. A., Laport, G. G., Miklos, D. B., Johnston, L. J., Arai, S., Weng, W., Hoppe, R. T., Lavori, P. W., Blume, K. G., Negrin, et al
2009; 114 (5): 1099-1109
 - **Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma** *LEUKEMIA & LYMPHOMA*
Timmerman, J. M., Vose, J. M., Czerwinski, D. K., Weng, W., Ingolia, D., Mayo, M., Denney, D. W., Levy, R.
2009; 50 (1): 37-46
 - **Genetic polymorphism of the inhibitory IgG Fc receptor FcγRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab** *LEUKEMIA & LYMPHOMA*
Weng, W. K., Levy, R.
2009; 50 (5): 723-727
 - **Immunoglobulin G Fc Receptor Polymorphisms Do Not Correlate with Response to Chemotherapy or Clinical Course in Patients with Follicular Lymphoma** *LEUKEMIA & LYMPHOMA*
Weng, W. K., Levy, R.
2009; 50 (9): 1494-1500
 - **A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma** *CLINICAL CANCER RESEARCH*
Racila, E., Link, B. K., Weng, W., Witzig, T. E., Ansell, S., Maurer, M. J., Huang, J., Dahle, C., Halwani, A., Levy, R., Weiner, G. J.
2008; 14 (20): 6697-6703
 - **The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells** *BLOOD*
Luqman, M., Klabunde, S., Lin, K., Georgakis, G. V., Cherukuri, A., Holash, J., Goldbeck, C., Xu, X., Kadel, E. E., Lee, S. H., Aukerman, S. L., Jallal, B., Aziz, et al
2008; 112 (3): 711-720
 - **Humoral immune response and immunoglobulin G Fc receptor genotype are associated with better clinical outcome following idiotype vaccination in follicular lymphoma patients regardless their response to induction chemotherapy.** *BLOOD*
Weng, W. K., Czerwinski, D., Levy, R.
2007; 109: 951-3

- **Immune-mediated antitumor effects with antibody therapy.** *American Society of Clinical Oncology Educational Book*
Weng WK
2005; 200-4
- **Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype.** *JOURNAL OF CLINICAL ONCOLOGY*
Weng, W. K., Czerwinski, D., Timmerman, J., Hsu, F. J., Levy, R.
2004; 22: 4717
- **Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma** *JOURNAL OF CLINICAL ONCOLOGY*
Weng, W. K., Levy, R.
2003; 21 (21): 3940-3947
- **Hepatitis C virus (HCV) and lymphomagenesis** *LEUKEMIA & LYMPHOMA*
Weng, W. K., Levy, S.
2003; 44 (7): 1113-1120
- **Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma** *BLOOD*
Weng, W. K., Levy, R.
2001; 98 (5): 1352-1357
- **Differential induction of DNA-binding activities following CD19 cross-linking in human B lineage cells** *JOURNAL OF IMMUNOLOGY*
Weng, W. K., Shah, N., O'Brien, D., Van Ness, B., LeBien, T. W.
1997; 159 (11): 5502-5508
- **SIGNALING THROUGH CD19 ACTIVATES VAV MITOGEN-ACTIVATED PROTEIN-KINASE PATHWAY AND INDUCES FORMATION OF A CD19/VAV/PHOSPHATIDYLINOSITOL 3-KINASE COMPLEX IN HUMAN B-CELL PRECURSORS** *JOURNAL OF BIOLOGICAL CHEMISTRY*
Weng, W. K., Jarvis, L., LeBien, T. W.
1994; 269 (51): 32514-32521
- **FUNCTIONAL EFFECT OF IL-7-ENHANCED CD19 EXPRESSION ON HUMAN B-CELL PRECURSORS** *JOURNAL OF IMMUNOLOGY*
Wolf, M. L., Weng, W. K., STIEGLBAUER, K. T., Shah, N., LeBien, T. W.
1993; 151 (1): 138-148